Limits...
Neuropilins: a new target for cancer therapy.

Grandclement C, Borg C - Cancers (Basel) (2011)

Bottom Line: Since many types of tumor and endothelial cells express NRP receptors, various soluble molecules were also found to interact with these receptors to modulate cancer progression.Although NRP genes share 44% homology, differences in their expression patterns, ligands specificities and signaling pathways were observed.Indeed, NRP2 may regulate tumor progression by several concurrent mechanisms, not only angiogenesis but lymphangiogenesis, epithelial-mesenchymal transition and metastasis.

View Article: PubMed Central - PubMed

Affiliation: INSERM UMR 645, F-25020 Besançon, France. camille.grandclement@gmail.com.

ABSTRACT
Recent investigations highlighted strong similarities between neural crest migration during embryogenesis and metastatic processes. Indeed, some families of axon guidance molecules were also reported to participate in cancer invasion: plexins/semaphorins/neuropilins, ephrins/Eph receptors, netrin/DCC/UNC5. Neuropilins (NRPs) are transmembrane non tyrosine-kinase glycoproteins first identified as receptors for class-3 semaphorins. They are particularly involved in neural crest migration and axonal growth during development of the nervous system. Since many types of tumor and endothelial cells express NRP receptors, various soluble molecules were also found to interact with these receptors to modulate cancer progression. Among them, angiogenic factors belonging to the Vascular Endothelial Growth Factor (VEGF) family seem to be responsible for NRP-related angiogenesis. Because NRPs expression is often upregulated in cancer tissues and correlated with poor prognosis, NRPs expression might be considered as a prognostic factor. While NRP1 was intensively studied for many years and identified as an attractive angiogenesis target for cancer therapy, the NRP2 signaling pathway has just recently been studied. Although NRP genes share 44% homology, differences in their expression patterns, ligands specificities and signaling pathways were observed. Indeed, NRP2 may regulate tumor progression by several concurrent mechanisms, not only angiogenesis but lymphangiogenesis, epithelial-mesenchymal transition and metastasis. In view of their multiples functions in cancer promotion, NRPs fulfill all the criteria of a therapeutic target for innovative anti-tumor therapies. This review focuses on NRP-specific roles in tumor progression.

No MeSH data available.


Related in: MedlinePlus

Neuropilins (NRPs) and their ligands. Class-3 semaphorins bind a1/a2 sub-units (green) whereas vascular-endothelial growth factors preferentially bind b1/b2 sub-units (blue). Other growth factors such as HGF, B-FGF, TGFβ1 have been recently reported to bind both NRPs (yellow).
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3757396&req=5

f1-cancers-03-01899: Neuropilins (NRPs) and their ligands. Class-3 semaphorins bind a1/a2 sub-units (green) whereas vascular-endothelial growth factors preferentially bind b1/b2 sub-units (blue). Other growth factors such as HGF, B-FGF, TGFβ1 have been recently reported to bind both NRPs (yellow).

Mentions: A major distinction between these two members of the NRP family is based on their ligand specificities. NRPs were originally described as high-affinity cell-surface receptors for axon guidance molecules such as class-3 semaphorins (Sema) [6]. Indeed, NRP1 is a receptor for semaphorin-3A, 3C, 3F [5,6] while NRP2 preferentially binds Semaphorin 3B, 3C, 3D, 3F [7,8] (Figure 1).


Neuropilins: a new target for cancer therapy.

Grandclement C, Borg C - Cancers (Basel) (2011)

Neuropilins (NRPs) and their ligands. Class-3 semaphorins bind a1/a2 sub-units (green) whereas vascular-endothelial growth factors preferentially bind b1/b2 sub-units (blue). Other growth factors such as HGF, B-FGF, TGFβ1 have been recently reported to bind both NRPs (yellow).
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3757396&req=5

f1-cancers-03-01899: Neuropilins (NRPs) and their ligands. Class-3 semaphorins bind a1/a2 sub-units (green) whereas vascular-endothelial growth factors preferentially bind b1/b2 sub-units (blue). Other growth factors such as HGF, B-FGF, TGFβ1 have been recently reported to bind both NRPs (yellow).
Mentions: A major distinction between these two members of the NRP family is based on their ligand specificities. NRPs were originally described as high-affinity cell-surface receptors for axon guidance molecules such as class-3 semaphorins (Sema) [6]. Indeed, NRP1 is a receptor for semaphorin-3A, 3C, 3F [5,6] while NRP2 preferentially binds Semaphorin 3B, 3C, 3D, 3F [7,8] (Figure 1).

Bottom Line: Since many types of tumor and endothelial cells express NRP receptors, various soluble molecules were also found to interact with these receptors to modulate cancer progression.Although NRP genes share 44% homology, differences in their expression patterns, ligands specificities and signaling pathways were observed.Indeed, NRP2 may regulate tumor progression by several concurrent mechanisms, not only angiogenesis but lymphangiogenesis, epithelial-mesenchymal transition and metastasis.

View Article: PubMed Central - PubMed

Affiliation: INSERM UMR 645, F-25020 Besançon, France. camille.grandclement@gmail.com.

ABSTRACT
Recent investigations highlighted strong similarities between neural crest migration during embryogenesis and metastatic processes. Indeed, some families of axon guidance molecules were also reported to participate in cancer invasion: plexins/semaphorins/neuropilins, ephrins/Eph receptors, netrin/DCC/UNC5. Neuropilins (NRPs) are transmembrane non tyrosine-kinase glycoproteins first identified as receptors for class-3 semaphorins. They are particularly involved in neural crest migration and axonal growth during development of the nervous system. Since many types of tumor and endothelial cells express NRP receptors, various soluble molecules were also found to interact with these receptors to modulate cancer progression. Among them, angiogenic factors belonging to the Vascular Endothelial Growth Factor (VEGF) family seem to be responsible for NRP-related angiogenesis. Because NRPs expression is often upregulated in cancer tissues and correlated with poor prognosis, NRPs expression might be considered as a prognostic factor. While NRP1 was intensively studied for many years and identified as an attractive angiogenesis target for cancer therapy, the NRP2 signaling pathway has just recently been studied. Although NRP genes share 44% homology, differences in their expression patterns, ligands specificities and signaling pathways were observed. Indeed, NRP2 may regulate tumor progression by several concurrent mechanisms, not only angiogenesis but lymphangiogenesis, epithelial-mesenchymal transition and metastasis. In view of their multiples functions in cancer promotion, NRPs fulfill all the criteria of a therapeutic target for innovative anti-tumor therapies. This review focuses on NRP-specific roles in tumor progression.

No MeSH data available.


Related in: MedlinePlus